DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

The Directorate General of Foreign Trade ( DGFT ) has notified an extension in the deadline for submitting applications for the export of Pharma Grade Sugar. This was communicated through Trade Notice No. 09/2025-26, dated July 22, 2025.

As per the latest trade notice, the revised deadline for submission of applications for obtaining Export Authorisation has been extended to July 31, 2025. This extension follows the earlier communication under Trade Notice No. 06/2025-26 issued on June 18, 2025, which had originally set the deadline.

The notice stated that “In continuation to the earlier Trade Notice No. 06/2025-26 dated June 18, 2025, the last date for submission of application for Export Authorisation for Pharma Grade Sugar, has been extended up to July 31, 2025. All other contents of the Trade Notice remains unchanged.”

Comprehensive Guide of Law and Procedure for Filing of Income Tax Appeals, Click Here

According to the directorate, all other terms and conditions mentioned in the earlier notice are still in effect. With the high standards and sensitive nature of exporting pharmaceutical-grade sugar, the delay is meant to provide exporters more time to finish the required paperwork and regulatory compliance.

This announcement has been circulated to all Regional Authorities of DGFT, Customs Commissionerates, and members of the trade community. For any further clarification, stakeholders have been advised to contact the DGFT.

Related Posts

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

New Delhi: AstraZeneca’s India-arm has partnered with National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, to build clinical research capabilities at 25 emerging geographies in a bid to extend…

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Following a bumpy regulatory road that involved a refusal-to-file, ImmunityBio has won FDA approval to expand Anktiva into papillary-only non-muscle-invasive bladder cancer (NMIBC). Wednesday’s approval comes nearly three months ahead…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

Governments have moved for Price Transparency in Hospitals to help patients cope with bills

Governments have moved for Price Transparency in Hospitals to help patients cope with bills

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction